ViroCell Biologics and AvenCell Therapeutics to accelerate development of novel allogeneic CAR-T therapies for blood cancers August 5, 2025
Patient death triggers switch to standard FC Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in 1L Consolidation for LBCL August 5, 2025
Positive Data Announced from Ph 2 CRDF-004 trial of onvansertib in 1L RAS-mutated mCRC August 5, 2025
Supplemental NDA submitted to FDA for fixed-duration, all-oral combo regimen of VENCLEXTA and acalabrutinib in 1L CLL patients August 5, 2025
First Patient Dosed in Ph 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer August 5, 2025
Final Clinical Data Update from the NXP800 Ph 1b Study in Ovarian Cancer Provided and Completion of the NXP900 Ph 1a Dose Escalation Study Reported August 5, 2025
Positive FDA Feedback and Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer Announced August 5, 2025
LIfT BioSciences granted €12M from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy August 5, 2025
ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha RLTs and Expand Manufacturing and Supply Chain Infrastructure August 5, 2025
Clinical Evaluation of SON-1010 Dose Escalation Expanded with Atezolizumab in Ovarian Cancer August 5, 2025
First patient dosed in pivotal Ph 3 AK112-305/HARMONi-8A trial of ivonescimab + docetaxel for PD-1/L1i & chemo-refractory NSCLC August 5, 2025
Targeted Enrollment Completed for Lung Cancer Ph 2 Harmonic™ Trial in Japan for LP-300 August 5, 2025
Jaypirca (pirtobrutinib) met primary endpoint in a head-to-head Ph 3 trial versus Imbruvica (ibrutinib) in CLL/SLL August 5, 2025
Preliminary Safety & Efficacy Data Announced from Trial of IMM2510/AXN-2510 in Combination with Chemo in 1L NSCLC in China August 5, 2025
Approval of the third of four stages of the Ph 1/2 study of AB8939 in R/R AML patients announced August 5, 2025
FDA Fast Track Designation for CLD-201 (SuperNova) for the Treatment of Patients with Soft Tissue Sarcoma August 5, 2025
JSKN003 Received FDA IND Approval to Initiate Ph 2 Study for Platinum-Resistant Ovarian Cancer August 5, 2025
